Abstract: Human sirtuin 2 (SIRT2), a member of the sirtuin family, has been considered as a promising drug target in cancer, neurodegenerative diseases, type II diabetes, and bacterial infections. Thus, SIRT2 inhibitors have been involved in effective treatment strategies for related diseases. Using previously established fluorescence-based assays for SIRT2 activity tests, the authors screened their in-house database and identified a compound, 4-(5-((3-(quinolin-5-yl)ureido)methyl) furan-2-yl)benzoic acid (20), which displayed 63 ± 5% and 35 ± 3% inhibition against SIRT2 at 100 µM and 10 µM, respectively. The structure-activity relationship (SAR) analyses of a series of synthesized (5-phenylfuran-2-yl)methanamine derivatives led to the identification of a potent compound 25 with an IC 50 value of 2.47 µM, which is more potent than AGK2 (IC 50 = 17.75 µM). Meanwhile, 25 likely possesses better water solubility (cLogP = 1.63 and cLogS = −3.63). Finally, the molecular docking analyses indicated that 25 fitted well with the induced hydrophobic pocket of SIRT2.
Introduction
Histone deacetylases (HDACs) are enzymes that catalyze the removal of acyl groups from ε-N-acyl-lysine amino groups on histones and non-histone substrates. These have been identified and grouped into four classes [1] [2] [3] : Classes I, II, and IV HDACs are Zn 2+ -dependent metalloproteases; class III HDACs, namely sirtuins (SIRTs), use NAD + as a cofactor for catalysis [4] [5] [6] . There are seven isotypes of sirtuins (SIRT1-7), which differ in their catalytic activity and subcellular localization [7] . The isotype SIRT2, which is located in both cytoplasm and nucleus [8] , mainly catalyzes deacetylation and defatty-acylation for a variety of protein substrates, including histones H3 and H4 [9, 10] , and nonhistone proteins α-tubulin [11] , p53 [12] , Foxo1 [13] , p300 [14] , NFκB [15] , PAR3 and PRLR [16] . Thus, SIRT2 has been shown to be involved in cell cycle regulation [11, 17, 18] , autophagy [19] , peripheral myelination [20] , and immune and inflammatory responses [21] [22] [23] . Recently, many studies revealed that the dysregulation of SIRT2 activity is a key factor contributing to the pathogenesis of cancer [24] , neurodegenerative diseases [25, 26] , type II diabetes [27] , and bacterial infections [21, 23] , which makes SIRT2 a promising target for pharmaceutical intervention.
To date, except for some substrate analogues [7] , a number of small molecule inhibitors targeting SIRT2 have been reported. The representative inhibitors are shown in Figure 1 : The moderate potency or non-specific inhibitors Sirtinol (46 µM) [28] , EX-527 (46 µM) [29, 30] , AGK2 (3.5 µM) [31, 32] , AEM1(18.5 µM) [33] , AK-7 (15.5 µM) [34] , and AC-93253 (6 µM) [35] , the highly potent but unselective inhibitors VII (0.048 µM) and VIII (0.001 µM) [36] , and the potent and highly isotype-selective SIRT2 inhibitor SirReal2 (0.4 µM) [23, 37] . However, there remains a shortage of novel SIRT2 inhibitors as lead candidates for drug discovery and development. The authors previously established a fluorescence-based method for SIRT2 inhibition tests [38] [39] [40] , and identified a series of N- (3-(phenoxymethyl) phenyl)acetamide derivatives as highly selective SIRT2 inhibitors [38, 41] , some of which showed inhibitory activities against SIRT2 highly-expressed human breast cancer cells and non-small cell lung cancer cells. Recently, the in-house compound collection using the fluorescence-based method was screened, and a new compound was identified, 4-(5-((3-(quinolin-5-yl)ureido)methyl)furan-2-yl)benzoic acid (20, Figure 2 ), which displayed 63 ± 5% and 35 ± 3% inhibition against SIRT2 at 100 μM and 10 μM, respectively ( Table 1 ). The scaffold of compound 20 is novel for SIRT2 inhibitors, and 20 has a relatively low molecular weight (387 Da) with moderate physicochemical properties (cLogP = 3.05, cLogS = −4.04). Thus, in this study, the authors used 20 as a starting point for further structural modifications (Linker, A, B, Figure 2 ) to improve the inhibitory potency against SIRT2. 
Results and Discussion

Chemistry
This study synthesized a series of (5-phenylfuran-2-yl)methanamine derivatives using the synthetic routes outlined in Schemes 1-3. Firstly, urea-based compounds 11-19 were acquired through the condensation reaction between the key intermediate 5a-5i with aromatic-amine compounds 6-10 in the presence of triphosgene, in 82-93% yields (Scheme 1). The intermediates 5a- The authors previously established a fluorescence-based method for SIRT2 inhibition tests [38] [39] [40] , and identified a series of N-(3-(phenoxymethyl)phenyl)acetamide derivatives as highly selective SIRT2 inhibitors [38, 41] , some of which showed inhibitory activities against SIRT2 highly-expressed human breast cancer cells and non-small cell lung cancer cells. Recently, the in-house compound collection using the fluorescence-based method was screened, and a new compound was identified, 4-(5-((3-(quinolin-5-yl)ureido)methyl)furan-2-yl)benzoic acid (20, Figure 2 ), which displayed 63 ± 5% and 35 ± 3% inhibition against SIRT2 at 100 µM and 10 µM, respectively ( Table 1 ). The scaffold of compound 20 is novel for SIRT2 inhibitors, and 20 has a relatively low molecular weight (387 Da) with moderate physicochemical properties (cLogP = 3.05, cLogS = −4.04). Thus, in this study, the authors used 20 as a starting point for further structural modifications (Linker, A, B, Figure 2 ) to improve the inhibitory potency against SIRT2.
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Next, the desired target compound 30, a hydroxamic acid derivative, was prepared by a three-step sequence starting from the synthesized intermediate 4a (Scheme 2). Sodium cyanoborohydride (NaBH 3 CN)-mediated reduction reaction was firstly performed to reduce the aldoxime group of intermediate 4a to the hydroxylamine of intermediate 27 (54% yield), followed by condensation with 2-phenylacetyl chloride in the presence of NaHCO 3 to give the compound 29. Further, hydrolysis of compound 29 using 3.0 equiv NaOH led to the white solid target compound 30. The synthesis of target compounds 32-37 are also depicted in Scheme 2. The reactions of commercially available amines (aniline, phenylmethanamine, and pyridin-3-ylmethanamine) or hydrazide (nicotinohydrazide) with intermediates 3a or 3i in the presence of hantzschester (1.2 equiv), catalytic amount of molecular sieve and trifluoroacetic acid, resulted in the reductive amination products 31-34. The resulting compounds 31-33 were subsequently hydrolyzed to give the desired compounds 35-37 in high yields. Finally, Scheme 3 presents the synthetic routes for compounds 39 and 43-52, which contain a sulfonamide or amide linker. For sulfonamide linker compound 39, intermediate 5a was used to react with benzenesulfonyl chloride in the presence of Et3N at room temperature, and the resulting compound 38 underwent a hydrolysis reaction to give the desired target compound 39, in 80% yield for two steps. The synthetic access to structurally diverse amide linker compounds 41-48 was achieved using a condensation reaction of carboxylic acid (40) with amine (5a, 5c-5f) in the presence of 1-hydroxybenzotriazole (HOBT), 1-(3-(dimethylamino)propyl)-3-ethylcarbodiimide hydrochloride (EDCI), and N,N-diisopropylethylamine (DIPEA). The resulting ester-contained compounds 41, 42, 46 and 47 were subjected to hydrolyzation to afford the target compounds 49-52 in good yields. Finally, Scheme 3 presents the synthetic routes for compounds 39 and 43-52, which contain a sulfonamide or amide linker. For sulfonamide linker compound 39, intermediate 5a was used to react with benzenesulfonyl chloride in the presence of Et3N at room temperature, and the resulting compound 38 underwent a hydrolysis reaction to give the desired target compound 39, in 80% yield for two steps. The synthetic access to structurally diverse amide linker compounds 41-48 was achieved using a condensation reaction of carboxylic acid (40) with amine (5a, 5c-5f) in the presence of 1-hydroxybenzotriazole (HOBT), 1-(3-(dimethylamino)propyl)-3-ethylcarbodiimide hydrochloride (EDCI), and N,N-diisopropylethylamine (DIPEA). The resulting ester-contained compounds 41, 42, 46 and 47 were subjected to hydrolyzation to afford the target compounds 49-52 in good yields. Finally, Scheme 3 presents the synthetic routes for compounds 39 and 43-52, which contain a sulfonamide or amide linker. For sulfonamide linker compound 39, intermediate 5a was used to react with benzenesulfonyl chloride in the presence of Et 3 N at room temperature, and the resulting compound 38 underwent a hydrolysis reaction to give the desired target compound 39, in 80% yield for two steps. The synthetic access to structurally diverse amide linker compounds 41-48 was achieved using a condensation reaction of carboxylic acid (40) with amine (5a, 5c-5f) in the presence of 1-hydroxybenzotriazole (HOBT), 1-(3-(dimethylamino)propyl)-3-ethylcarbodiimide hydrochloride (EDCI), and N,N-diisopropylethylamine (DIPEA). The resulting ester-contained compounds 41, 42, 46 and 47 were subjected to hydrolyzation to afford the target compounds 49-52 in good yields. 
SAR Studies with SIRT2
The enzyme activity assays were performed using a fluorogenic-based method [38] [39] [40] , and Ac-Glu-Thr-Asp-Lys(Dec)-AMC, termed p2270, was used as the substrate. The SAR studies with all of the synthesized (5-phenylfuran-2-yl)methanamine derivatives (Tables 1 and 2) were carried out. The compounds bearing various linkers or different substituents (A moiety) at 3-or 4-position of the phenyl of (5-phenylfuran-2-yl)methanamine scaffold (Table 1) were firstly investigated. Compared with the hit compound 20, compounds 12 and 21, containing a urea as linker, showed comparable or slightly lower SIRT2 inhibitory activities at 100 µM or 10 µM;.Carboxyl acid which contained compounds 20 and 21, appeared to have better clogP and clogS properties than 12 (with clogP of 5.14 and clogS of −4.43). Compound 22 (23 ± 3%), bearing a thiourea linker, displayed lower inhibitory activity to SIRT2 than the corresponding compound 21 (33 ± 3%) at 10µM. Further comparison of the different linkers, including hydroxamic acid (30) , secondary amine (35, 36) , sulfonamide (39) and amide (49, 50) revealed that urea linker derivatives were likely to have more potent SIRT2 inhibition than other linker derivatives. The additional compounds with the 4-ethyl formate (32), 4-methyl (43), 4-methoxy group (44) replaced the 4-carboxyl of the phenyl of (5-phenylfuran-2-yl)methanamine scaffold or changed to 3-position substituents (45-47, 51, and 52) did not show improved inhibitory activity against SIRT2. These results indicate that the urea linker and 4-carboxyl of the phenyl of (5-phenylfuran-2-yl)methanamine scaffold may be beneficial to fit with the binding pocket of SIRT2. 
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The authors next synthesized compounds 23-26, which contain a urea linker and 4-carboxyl of the phenyl of (5-phenylfuran-2-yl)methanamine. The tested inhibitory activities and calculated clogP and clogS values are shown in Table 2 . Compounds 23, 24, and 26 appear to have moderate physiochemical properties, but compound 25, with the pyridine moiety, likely possesses better water solubility (cLogP = 1.63 and cLogS = −3.63). Notably, compound 25 (99 ± 2% @ 100 μM, 90 ± 3% @ 10 μM) shows potent inhibition against SIRT2, which is substantially more potent than the structurally similar compound AGK2 (80 ± 6% @ 100 μM, 30 ± 5% @ 10 μM). Considering the fact that the introduction of pyridine at the skeleton has improved SIRT2 inhibition, a series of pyridine-containing (5-phenylfuran-2-yl)methanamine derivatives (17, 18, 33, 34, 37 and 48) were further synthesized. Comparing with 25, only compounds 17 (50 ± 4% @ 100 μM, 37 ± 3% @ 10 μM) and 18 (40 ± 5% @ 100 μM, 23 ± 2% @ 10 μM), which both contained a urea linker, displayed low inhibition to SIRT2, whereas compounds 33, 34, 37 and 48 had almost no SIRT2 inhibitory activities (Table 2) . 1 Each compound was tested in triplicate; the data are presented as the mean ± SD (n = 2).
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Collectively, the structural optimization and SAR studies led to the discovery of compound 25, which exhibited high potency against SIRT2, better than the hit compound 20 and positive control AGK2. Subsequently, the IC 50 value of 25 was then measured against SIRT2, and the IC 50 curve has been presented in Figure 3 . The study observed that compound 25 inhibited SIRT2 via a dose dependent manner with an IC 50 value of 2.47 µM, which is more potent than AGK2 (with an IC 50 value of 17.75 µM). Molecular docking was then used to investigate the possible binding mode of 25 with SIRT2. The results indicated that 25 appeared to fit well with the induced hydrophobic pocket (Figure 4) [44, 45] . The carboxyl acid group of 25 is likely positioned to make hydrogen-bonding interactions with the main chain of Asp170 and the side chain of Thr171 and Tyr139. The furan and pyridine moiety likely have hydrophobic contacts with hydrophobic residues Phe119, Phe234, Phe131, Leu138, and Ile169 (Figure 4) . Notably, the pyridine appears to form edge-to-face aromatic interactions with Phe119, and fits well with the pocket around Phe119, Phe131, and Phe234, suggesting that introducing substituents on pyridine may result in a clash with these three residues. Together, these docking results may explain why the replacement of the carboxyl acid group or the introduction of substituents on pyridine leads to a decrease in SIRT2 inhibition, and indicates the possible inhibition mode for this series of compounds. 1 Each compound was tested in triplicate; the data are presented as the mean ± SD (n = 2).
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Materials and Methods
Synthesis
As previously reported, proton ( 1 H) and carbon ( 13 C) NMR spectra were recorded on a Bruker AV-400 (Bruker Company, Billerica, Germany) instrument and are reported in ppm relative to tetramethylsilane (TMS) and referenced to the solvent in which the spectra were collected. Unless otherwise noted, all of the commercially available starting materials, reagents, and solvents and reagents were used without further purification. The analytical thin-layer chromatography (TLC) was run on Merck silica gel 60 F-254 (Qingdao Haiyang, Qingdao, China). The spots on the plates were visualized under UV light (λ = 254 nm). Purification was performed on silica gel chromatography with EtOAc-petroleum ether or CH2Cl2-MeOH solvent systems. The melting points were measured on an electrothermal melting point apparatus without correction (JIAHANG, Shanghai, China. ESI-MS was obtained on a Shimadzu-2010EV series liquid chromatograph mass spectrometer (Shimadzu, Tokyo, Japan). High-resolution mass spectra (HRMS) were determined using a SCIEX X500 QTOF mass spectrometer (Shanghai Sciex Analytical Instrument Trading Co., Shanghai, China). All target compounds were purified to >95% purity, as determined by the high-performance liquid chromatography (HPLC). The HPLC analysis was performed on a Waters 2695 HPLC system equipped with a Kromasil C18 column (4.6 mm × 250 mm, 5 μm, Waters, Milford, MA, USA). 
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General Procedure for the Preparation of Key Intermediates 5a-5i
A mixture of substituted iodobenzenes (1a-1i, 15 mmol), (5-formylfuran-2-yl)boronic acid (2, 15 mmol), bis(triphenylphosphine)palladium(II) chloride (Pd(Pph 3 ) 2 Cl 2 , 0.6 mmol) and sodium carbonate (Na 2 CO 3 , 30 mmol) in MeCN/H 2 O (10 mL /10 mL) was stirred for 1 h at 60 • C. Upon completion of the reaction as determined by TLC, MeCN was removed by a rotary evaporator under reduced pressure, and the residue was acidated with 1M HCl solution (pH 7) and filtered. Next, the filtrate was partitioned between water (60 mL) and ethyl acetate (3 × 50 mL). The organic layer was dried over magnesium sulfate anhydrous (MgSO 4 ), filtered and concentrated in vacuo. The crude products were purified by column chromatography with appropriate eluents to give the coupling products 3a-3i, in 80-86% yields.
To a solution of the coupling products 3a-3i (12 mmol) in EtOH (25 mL), hydroxylamine hydrochloride (NH 2 OH.HCl, 14.4 mmol) and sodium acetate (NaOAc, 14.4 mmol) were added and the mixture was stirred at reflux for 0.5 h. When TLC indicated that the reaction was finished, the reaction solution was concentrated and the residue was partitioned between water (50) and ethyl acetate (3 × 50 mL). The combined organic layer was dried over MgSO 4 , filtered and concentrated in vacuo to give the crude products 4a-4i, which were used without further purification. Subsequently, to a stirring solution of condensation products, 4a-4i (12 mmol) in EtOH (25 mL) was added to zinc powder (Zn, 12 mmol) and 3 M hydrochloric acid (HCl, 8.0 mL) at ambient temperatures. The reaction mixture was heated to 80 • C for further 2 h. After completion (monitored by TLC), the solvent was removed in vacuo, the crude residue was treated with 100 mL of ice water, and the pH was adjusted to 7-8 with saturated NaHCO 3 . Then, the mixture was filtered by diatomite and extracted with ethyl acetate (3 × 80 mL). The combined extracts were dried, concentrated and purified by column chromatography with appropriate eluents with three ethylamine (Et 3 N, TEA) to afford the desired intermediates 5a-5i in high yields.
1-((5-(2,5-Dichlorophenyl)furan-2-yl)methyl)-3-(quinolin-5-yl)urea (12) . A solution of quinolin-5-amine (7, 250 mg, 1.73 mmol) and TEA (200 µL, 2.03 mmol) dissolved in CH 2 Cl 2 (DCM, 15 mL) was slowly dripped into a stirred solution of triphosgene (BTC, 256 mg, 0.85 mmol) in DCM (10 mL) by using a constant-pressure dropping funnel. Then, the mixture was stirred for another 0.5 h at room temperature (RT). After evaporation of the solvent, the residue was taken up in DCM (30 mL), and (5-(2,5-dichlorophenyl)furan-2-yl)methanamine (5b, 230 mg, 0.95 mmol) was added directly to the residue. The reaction mixture was stirred at RT for 6 h, and the solvent was subsequently removed in vacuo. The residue obtained was purified by column chromatography (V(PE):V(EA) = 1:1) to give the desired target compound 12 (343 mg, 0.84 mmol) in 88% yield. 96.8% HPLC purity. Mp: 245-246 • C. To a solution of substituted 5-phenylfuran-2-carbaldehydes (3a and 3i, 1.5 mmol), different amines (1.8 mmol) and diethyl 2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate (hantzschester, 1.8 mmol) in DCM (25 mL), catalytic amount of molecular sieve and trifluoroacetic acid were added at room temperature, and the reaction was warmed to 45 • C and reacted for 6-12 h. After completion (monitored by TLC), the reaction was filtered, and the crude residue was obtained by concentrating the filtrate in vacuo. Finally, the crude residue was purified by column chromatography to give the desired compounds 31-34 in high yields. 
Inhibition Assays
This study tested the inhibitory activities of the synthesized compounds against recombinant human SIRT2 proteins using a fluorogenic substrate p2270(Ac-Glu-Thr-Asp-Lys(Dec)-AMC)-coupled trypsin assay. The assay buffer is 25 mM Tris-HCl pH 8.0, 150 mM NaCl, and 10% glycerol. The test compounds were added to 60 µL of reaction mixture containing SIRT2 enzymes (0.2 µM), and each compound was prepared in a 3-fold dilution series (300 µM-15 nM) with the final DMSO concentration < 1%. After incubation at 25 • C for 30 min, the reaction started by the addition of the substrate p2270 (10 mM) and NAD + (400 mM) at 25 • C. After 2 h, 50 µL 3~4 U/µL trypsin and 4 mM nicotinamide were added to terminate the reaction, followed by further incubation for 30 min at 25 • C. The fluorescence intensity was measured using a microplate reader (λ ex = 380 nm, λ em = 460 nm). All determinations were performed in triplicate. The IC 50 values were obtained using GraphPad Prism software as described previously.
Molecular Docking Assays
All the docking simulations were performed using AutoDock Vina. The crystal structure of SIRT2 complexed with an N-(3-(phenoxymethyl)phenyl)acetamide derivative (24a) (PDB ID: 5YQO) and was used as the docking template. All the water and solvant molecules, as well as 24a were removed, and clean protein structure coordinates were obtained. AutoDockTools was used to assign Gasteiger-Marsili charges to the protein structure model, and merge non-polar hydrogens onto their respective heavy atoms of the protein structure (saved as pdbqt format). The 3D coordinates of the compound structures were prepared using the Discovery Studio viewer, followed by assigning atom types and partial charges using AutoDockTools (saved as pdbqt format). The binding site was defined as a rectangular grid, with the grid center coordinates of [x, y, z = −13.5, −10.1, −18.4] and the grid size of [25, 25, 25] , to encompass the entire binding site. The number of possible docking poses were set as 10, and the other docking parameters were set as default. The docking results were inspected using PyMOL.
Conclusions
In this study, a series of (5-phenylfuran-2-yl)methanamine derivatives were synthesized. The SAR analyses of these compounds with SIRT2 led to the identification of compound 25 with 99 ± 2% @ 100 µM and 90 ± 3 % @ 10 µM inhibition against SIRT2. Meanwhile, 25 likely possesses better water solubility (cLogP = 1.63 and cLogS = −3.63). The IC 50 measurements revealed that 25 had considerable potency against SIRT2 with an IC 50 value of 2.47 µM, which is more potent than AGK2. The molecular docking analyses indicated that 25 fits well with the induced hydrophobic pocket of SIRT2. This study will aid future investigations to discover new potent and selective SIRT2 inhibitors to provide potential treatments for relevant diseases.
